CN1950376A - 莪术醇衍生物、含该衍生物的组合物及所述衍生物的制药用途 - Google Patents

莪术醇衍生物、含该衍生物的组合物及所述衍生物的制药用途 Download PDF

Info

Publication number
CN1950376A
CN1950376A CNA2005800144098A CN200580014409A CN1950376A CN 1950376 A CN1950376 A CN 1950376A CN A2005800144098 A CNA2005800144098 A CN A2005800144098A CN 200580014409 A CN200580014409 A CN 200580014409A CN 1950376 A CN1950376 A CN 1950376A
Authority
CN
China
Prior art keywords
rcumenol
pharmaceutically acceptable
acceptable salt
compound
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2005800144098A
Other languages
English (en)
Other versions
CN1950376B (zh
Inventor
王树龙
郭殿武
孟昭珂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Minsheng Pharmaceutical Co Ltd
Original Assignee
Hangzhou Minsheng Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Minsheng Pharmaceutical Co Ltd filed Critical Hangzhou Minsheng Pharmaceutical Co Ltd
Publication of CN1950376A publication Critical patent/CN1950376A/zh
Application granted granted Critical
Publication of CN1950376B publication Critical patent/CN1950376B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明提供了右式具有右式I结构的莪术醇衍生物或其药学上可接受的盐，其中，Y选自＝CHR2，－CH2R2，＝O，(右式II)－OH或－OR1；R1选自H、R、RCO或HO3S；所述的R选自H；饱和的或不饱和的直链C1－10烃基等；R2选自F；Cl；Br；I；H；－OH；－OR；－HSO3等；条件是R1、R2不同时为H。本发明也提供了含有所述衍生物或其药学上可接受的盐的抗肿瘤或抗病毒的药物组合物。本发明进一步提供了所述衍生物或其药学上可接受的盐在制备预防和/或治疗肿瘤或抗病毒的药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN2005800144098A 2004-05-26 2005-05-26 莪术醇衍生物、含该衍生物的组合物及所述衍生物的制药用途 Expired - Fee Related CN1950376B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNA2004100443364A CN1704417A (zh) 2004-05-26 2004-05-26 新化合物莪术醇衍生物
CN200410044336.4 2004-05-26
PCT/CN2005/000730 WO2005116036A1 (en) 2004-05-26 2005-05-26 Curcumol derivatives, the compositions comprising the same and the use of the same in the manufacture of medicament

Publications (2)

Publication Number Publication Date
CN1950376A true CN1950376A (zh) 2007-04-18
CN1950376B CN1950376B (zh) 2010-09-08

Family

ID=35450829

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2004100443364A Pending CN1704417A (zh) 2004-05-26 2004-05-26 新化合物莪术醇衍生物
CN2005800144098A Expired - Fee Related CN1950376B (zh) 2004-05-26 2005-05-26 莪术醇衍生物、含该衍生物的组合物及所述衍生物的制药用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNA2004100443364A Pending CN1704417A (zh) 2004-05-26 2004-05-26 新化合物莪术醇衍生物

Country Status (4)

Country Link
US (1) US7700584B2 (zh)
EP (1) EP1749830B1 (zh)
CN (2) CN1704417A (zh)
WO (1) WO2005116036A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114315855A (zh) * 2022-02-09 2022-04-12 贵州省中国科学院天然产物化学重点实验室 莪术醇类衍生物、制备方法及其在制备抗炎药物中的应用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1995056B (zh) * 2006-10-31 2011-06-15 温州医学院 新的莪术醇糖苷类化合物及其制备与应用
ES2393877T3 (es) * 2008-01-04 2012-12-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Derivados de epoxi-guayano y tratamiento del cáncer
TWI427117B (zh) 2008-05-30 2014-02-21 Nitto Denko Corp 光學元件用樹脂組成物、使用其之光學元件及光學鏡片之製造方法
CN101538259A (zh) * 2009-04-17 2009-09-23 杭州民生药业集团有限公司 蓬莪术环二烯的晶型a、其制备方法及其在制备抗肿瘤药物中的应用
CN101671345B (zh) * 2009-09-28 2011-06-15 桂林医学院 一种莪术醇半抗原和人工抗原及其制备方法
CN102584847B (zh) * 2012-03-09 2015-03-25 沈阳药科大学 一种抗单纯疱疹病毒hsv的莪术醇衍生物
CN102584846B (zh) * 2012-03-09 2015-03-25 沈阳药科大学 一种抗甲型h1n1流感病毒的莪术醇衍生物
CN102759625A (zh) * 2012-07-26 2012-10-31 桂林医学院 莪术醇单克隆抗体在含莪术醇类中药中的免疫分析应用
JP6255031B2 (ja) * 2012-11-15 2017-12-27 アメリカ合衆国 Ｈｉｖ及びｈｔｌｖに感染した患者を治療する方法
CN106344553B (zh) * 2016-08-03 2019-12-13 江西省妇幼保健院 莪术醇在制备用于通过干预子宫内膜间质细胞而达到治疗子宫腺肌病的药物中的用途
CN106674242B (zh) * 2016-11-21 2018-11-30 辽宁大学 一种具有抗肿瘤活性的莪术醇衍生物及其制备方法和应用
CN106632383B (zh) * 2016-11-21 2018-08-14 辽宁大学 莪术醇衍生物及其制备方法和在抗肿瘤药物中的应用
CN106800560B (zh) * 2016-12-23 2018-11-02 中国医学科学院药用植物研究所 莪术醇衍生物及其制备方法和应用
CN107828401B (zh) * 2017-06-08 2020-07-14 中国石油化工股份有限公司 一种增强co2与原油互溶、降低原油粘度的驱油添加剂
CN107828402B (zh) * 2017-06-08 2020-07-14 中国石油化工股份有限公司 一种提高深层稠油co2气驱过程采收率的化学添加剂
CN110604732B (zh) * 2019-09-20 2022-10-14 浙江工业大学 一种莪术醇衍生物在制备治疗结直肠癌药物中的应用
CN111153912B (zh) * 2019-12-31 2021-04-06 浙江工业大学 一种含三氮唑结构的莪术醇衍生物及其在制备治疗人结直肠癌药物中的应用
CN115433203A (zh) * 2021-06-01 2022-12-06 华东理工大学 一种胺氟化莪术醇衍生化合物及及其应用与制备方法
CN113336765B (zh) * 2021-06-16 2022-11-25 浙江工业大学 一种莪术醇酯化物、制备方法及其在治疗结直肠癌药物中的应用
CN113866319B (zh) * 2021-10-25 2022-05-31 广西壮族自治区海洋环境监测中心站 一种类固醇激素的检测方法
CN116173159B (zh) * 2021-11-28 2024-02-02 北京中医药大学东直门医院 莪术油磺化物及制备方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003951A (en) * 1972-06-05 1977-01-18 Givaudan Corporation Octahydroazulenols
CH571863A5 (zh) * 1972-06-05 1976-01-30 Givaudan & Cie Sa
US20040192641A1 (en) * 2003-03-14 2004-09-30 Yaguang Liu Special preparation of anticancer drugs made by novel nanotechnology

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114315855A (zh) * 2022-02-09 2022-04-12 贵州省中国科学院天然产物化学重点实验室 莪术醇类衍生物、制备方法及其在制备抗炎药物中的应用

Also Published As

Publication number Publication date
EP1749830B1 (en) 2013-12-11
WO2005116036A1 (en) 2005-12-08
US7700584B2 (en) 2010-04-20
CN1950376B (zh) 2010-09-08
EP1749830A4 (en) 2008-01-09
US20070191360A1 (en) 2007-08-16
CN1704417A (zh) 2005-12-07
EP1749830A1 (en) 2007-02-07

Similar Documents

Publication Publication Date Title
CN1950376A (zh) 莪术醇衍生物、含该衍生物的组合物及所述衍生物的制药用途
CN103961340B (zh) 一类lsd1抑制剂及其应用
JP2024503755A (ja) ウイルス感染症治療用ヌクレオシド系化合物及びその用途
CN102675403B (zh) 抗乙肝药物lqc-x的合成及其应用
CN103224530B (zh) 一组替诺福韦酯化合物、制备方法及其在抗病毒方面的应用
CN101058535B (zh) 二(7-羟基-2,3-二氢-1-1h-茚基)醚类及其类似物、合成方法及应用
WO2022188846A1 (zh) 一种三氮唑类衍生物及其制备方法和应用
JP7123417B2 (ja) 抗不安重水素化合物及びその医薬的用途
CN103360398B (zh) 一种三唑并嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
CN105503627B (zh) 一种新型棉酚希夫碱衍生物及其制备方法与应用
US8853194B2 (en) Sterol derivatives and their synthesis and use
CN110041342B (zh) 一种含硒化合物及其用途
CN111303235B (zh) 一种抗流感病毒化合物及其制备方法与应用
CN106478760A (zh) 具有抗肿瘤作用的三帖类衍生物tba-x及其制备方法和应用
KR101748229B1 (ko) 2,2'-비스-티아졸계 화합물 및 그 제조방법과 용도
CN103113285B (zh) 一种吲哚类化合物及其作为hiv-1逆转录酶抑制剂的应用
AU1372092A (en) Long chain antiviral compounds
Matsuya et al. Synthesis of new phorbol derivatives having ethereal side chain and evaluation of their anti-HIV activity
RU2649406C1 (ru) 3-n-замещенные борнилпропионаты, используемые в качестве ингибиторов вируса марбург
WO2004033443A1 (fr) Derives d'hexahydroxybiphenyles a substitution par halogene, leur preparation et leurs utilisations entant que medicaments
CN101328123B (zh) 5-氧-取代苯烯丙酰奎尼酸甲酯化合物及其用途
CN104211748B (zh) 6‑羟基双脱氧鸟嘌呤核苷磷酸酯制备和用途
CN109369634B (zh) 具有抗肿瘤活性的2-甲氧基烟酰胺衍生物制备方法及用途
CN115141206B (zh) 一种ɑ-硫辛酸石蒜碱偶联物及其制备方法和应用
RU2697716C1 (ru) Гидрохлорид 1,7,7-триметилбицикло[2.2.1]гептан-2-ил 3-(пиперидин-1-ил)пропионат, используемый в качестве ингибитора вируса Эбола

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20081219

Address after: No. 108 Tong Road, Hangzhou, Zhejiang, Yuhang, China

Applicant after: Hangzhou people's livelihood Pharmaceutical Group Co., Ltd.

Co-applicant after: Minsheng Pharmaceutical Group Shaoxing Medicine Co., Ltd.

Address before: No. 108 Tong Road, Hangzhou, Zhejiang, Yuhang, China

Applicant before: Hangzhou Minsheng Pharmaceutical Group Co., Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100908

Termination date: 20160526